News - Bristol-Myers Squibb

Filter

Current filters:

Bristol-Myers Squibb

Popular Filters

70 to 94 of 222 results

Bristol-Myers' data on Yervoy and nivolumab causes a stir

17-05-2013

Release of abstracts of presentations to be made at the forthcoming49th Annual Meeting of the American…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearchYervoy

IQWiG re-assessments come up with same view for saxagliptin and different for crizotinib

14-05-2013

Under the rules of the German Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute…

AstraZenecaBristol-Myers SquibbcrizotinibDiabetesEuropeKomboglyzeOncologyOnglyzaPfizerPharmaceuticalPricingRegulationsaxagliptinXalkori

Positive results from sub-analysis of Eliquis ARISTOTLE trial

07-05-2013

US drug major Bristol-Myers Squibb (NYSE: BMY) and partner Pfizer (NYSE: PFE) reported results from a…

Bristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalResearch

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Bristol-Myers 1st-qtr sales and EPS plunge, missing analysts' forecasts

25-04-2013

US drug major Bristol-Myers Squibb (NYSE: BMY) released first-quarter 2013 financial results, showing…

Bristol-Myers SquibbFinancialPharmaceutical

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon

23-04-2013

US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Santaris Pharma in multi-million dollar deal with Bristol-Myers for RNA-targeted medicines

17-04-2013

Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says it has entered into…

BiotechnologyBristol-Myers SquibbLicensingPharmaceuticalResearchSantaris Pharma

Bristol-Myers pumps about $250 million into biologics facility expansion

12-04-2013

Just a few days after announcing the closure of its biotech subsidiary Amylin facility in California…

BiotechnologyBristol-Myers SquibbFinancialPharmaceuticalProductionResearch

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress

09-04-2013

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) and US partner Johnson & Johnson (NYSE:…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirMerck & CoMK-5172PharmaceuticalResearchsimeprevirVaniprevirVictrelis

Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head

08-04-2013

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has entered into a non-exclusive agreement with pharma…

Anti-viralsBristol-Myers SquibbdaclatasvirManagementPharmaceuticalResearchVertexVX-135

Germany's IQWiG finds considerable added benefit for Bristol-Myers/Pfizer's Eliquis

05-04-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

Briefs: Pfizer $142 million fine upheld; Bristol-Myers shuts Amylin facility

05-04-2013

The US Court of Appeals in Boston has upheld a $142.1 million damage award to Kaiser Foundation Health…

AmylinBristol-Myers SquibbLegalManagementMarkets & MarketingNeurontinNorth AmericaPfizerPharmaceutical

Xarelto and Eliquis set to displace current therapies in DVT/PE

28-03-2013

Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

Germany's IQWiG finds no added benefit for AstraZeneca and Bristol-Myers' Forxiga

25-03-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Merck KGaA links with Bristol-Myers for Glucophage promotion in China

19-03-2013

German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

NICE green light for earlier use of Bristol-Myers' Orencia

08-03-2013

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) now recommends…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalRegulation

Germany's IQWiG finds no added benefit for Komboglyze or for Pixuvri

04-03-2013

In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

AstraZenecaBiotechnologyBristol-Myers SquibbCell TherapeuticsDiabetesEuropeKomboglyzemetforminOncologyPharmaceuticalPixuvriPricingRegulationsaxagliptin

Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds

26-02-2013

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those…

Bristol-Myers SquibbByettaDiabetesJanuviaMerck & CoPharmaceuticalResearch

70 to 94 of 222 results

Back to top